Targets › POLA2
1 program from 1 company in 12 trials: 5 Phase 3, 5 Phase 2, 2 Phase 4; Infectious disease; next expected readout Jul 2028.
Accessory subunit of the DNA polymerase alpha complex (also known as the alpha DNA polymerase-primase complex) which plays an essential role in the initiation of DNA synthesis. During the S phase of the cell cycle, the DNA polymerase alpha complex (composed of a catalytic subunit POLA1, an accessory subunit POLA2 and two primase subunits, the catalytic subunit PRIM1 and the regulatory subunit PRIM2) is recruited to…. (UniProt, Q14181)
Open in Phaseline: the race on POLA2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Merck & Co. (MSD) | Doravirine Human immunodeficiency virus type 1 reverse transcriptase negative allosteric modulator | RT, POLA2, POLG | Phase 3 | HIV-1 Infection; Human Immunodeficiency Virus (HIV) Infection; HIV-1-infection; HIV … | Jul 2028 |
HIV-1-infection (4) HIV-1 Infection (2) Human Immunodeficiency Virus (HIV) Infection (2) HIV (1) HIV - Human Immunodeficiency Virus (1) HIV Infections (1) Hiv (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.